(PA-289) Enhanced Expression of TAGLN2 Predicts Negative Prognosis in Multiple Myeloma

Transgelin-2 (TAGLN2), a cytoskeletal actin-binding protein involved in promoting tumorigenesis of human cancers. The association of TAGLN2 with multiple myeloma (MM) prognosis is unclear. Here, the clinical significance and potential function of TAGLN2 in MM were investigated.

Methods:   

RNA-Seq data were downloaded from MMRF CoMMpass dataset. Microarray and single cell RNA-seq datasets were downloaded from the Gene Expression Omnibus (GEO) database. We analyzed the differences in TAGLN2 expression between healthy donors and MM patients and between samples with different clinical information. The association of TAGLN2 with MM prognosis and immune infiltration were also analyzed.

Results:   

The expression of TAGLN2 showed an increasing trend with the progression of myeloma, and particularly showed higher levels in aggressive form of MM including plasma cell leukemia (PCL) and extramedullary MM. In addition, increased TAGLN2 expression was observed in the tumor cells from relapse MM compared to newly diagnosed MM (NDMM) or those without relapse. Survival analysis showed that high TAGLN2 expression level contributed to poor prognosis of MM patients. Functional enrichment analysis indicated that TAGLN2 may associated with cell cycle progression, cell adhesion and immune response in myeloma. Finally, we observed that TAGLN2 was distinctly correlated with tumor immunity in MM, evident by both increased immune cell infiltration and expressions of immune suppressive genes in myeloma cells, T cells, NK cells and monocytes.

Conclusions:   TAGLN2 might be used as reliable diagnostic and prognostic biomarker in MM.